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Abstract
Background. While polypharmacy is common in long-term residential psychiatric patients,
prescription combinations may, from an evidence-based perspective, be irrational. Potentially,
many psychiatric patients are treated on the basis of a poor diagnosis.We therefore evaluated the
DITSMI model (i.e., Diagnose, Indicate, and Treat Severe Mental Illness), an intervention that
involves diagnosis (or re-diagnosis) and appropriate treatment for severely mentally ill long-
term residential psychiatric patients. Our main objective was to determine whether DITSMI
affected changes over time regarding diagnoses, pharmacological treatment, psychosocial
functioning, and bed utilization.
Methods.DITSMI was implemented in a consecutive patient sample of 94 long-term residential
psychiatric patients during a longitudinal cohort study without a control group. The cohort was
followed for three calendar years. Data were extracted from electronic medical charts. As well as
diagnoses, medication use and currentmental status, we assessed psychosocial functioning using
the Health of the Nations Outcome Scale (HoNOS). Bed utilization was assessed according to
length of stay (LOS). Change was analyzed by comparing proportions of these data and testing
them with chi-square calculations. We compared the numbers of diagnoses and medication
changes, the proportions of HoNOS scores below cut-off, and the proportions of LOS before and
after provision of the protocol.
Results. Implementation of the DITSMI model was followed by different diagnoses in 49% of
patients, different medication in 67%, some improvement in psychosocial functioning, and a
40% decrease in bed utilization.
Conclusions. Our results suggest that DITSMI can be recommended as an appropriate care for
all long-term residential psychiatric patients.
Introduction
About 160,000 people in the Netherlands aged between 18 and 65 suffer from severe mental
illness (SMI) [1]. In the catchment area of the Mental Health Institute where this study was
conducted, the approximate number of patients with SMI was 12,000 [2].
According to Sterrenburg et al. [3], polypharmacy is common in the subgroup of patients with
SMI who have been hospitalized for longer periods. Due to the complexity and severity of these
patients’ psychiatric condition and comorbidity, polypharmacy—that is combining over four
psychotropic drugs—may be hard to avoid. The authors also concluded that, over time, reviews of
medication do not always lead to decreased use, but only to other combinations—often less
rational ones. Several studies have also warned that the combinations of medication prescribed
can lead to toxic dosages, potentially dangerous interactions, and serious side-effects
[3,4,5]. Tihonen et al. [5] showed benzodiazepine use to be associated with higher mortality
among patients with schizophrenia. Inadequate treatment using a variety of different medica-
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Although changing and simplifying medication sometimes
seems promising, patients, nurses, psychiatrists, and significant
others may regard it as risky. This perception may obstruct
adequate and rational treatment [7]. Many long-term residential
psychiatric patients have a long and difficult treatment history, in
which earlier relapses and perhaps aggression have made care
professionals, relatives and even patients themselves cautious about
change, thereby limiting the options for sensible and rational
adjustments in medication. Nonetheless, it is also important to
investigate whether treatment is still appropriate to the current
diagnosis. If one is unsuited to the other, the result—as various
studies have shown—will be incorrect treatment, over-treatment,
and avoidable side-effects [8–12].
Regular, structured evidence-based multidisciplinary assess-
ments and reassessments of diagnoses and treatment should thus
be viewed not only as appropriate, but also as necessary [13]. Suokas
et al. [14] showed that, as interventions in themselves, changes in
medication prescriptions were not enough to maintain inputs
intended to reduce medication. Despite this, we are aware of no
studies that investigated the effects of thoroughly reassessing diag-
noses and appropriateness of treatments in long-term residential
psychiatric patients. (Under “treatments,” we also include
evidence-based pharmacological, psychological and psychosocial
treatments.) We therefore developed the “Diagnose, Indicate, and
Treat Severe Mental Illness” (DITSMI) model, a pharmacological
protocol consistent with the current Dutch guidelines for
re-assessing patients with SMI on the basis of unbiased multi-
disciplinary holistic diagnoses and appropriate treatment
[15]. We expected implementation of the DITSMI model to pro-
duce (a) changed diagnoses that led to appropriate treatment,
(b) substantial changes in prescriptions, (c) improvements in psy-
chosocial functioning, and (d) changes in hospital-bed utilization.
Methods
The DITSMI model
Our objective with the DITSMImodel was to develop a protocol for
appropriate care in long-term residential psychiatric patients. The
model was based on a number of concepts and interventions,
including:
1. Holistic diagnosis, that is re-evaluating a patient with regard to
various aspects of life—including psychiatric, somatic and social
functioning—without relying solely on the DSM diagnosis
established earlier by a psychiatrist in the residential setting.
2. Appropriate treatment, including a multidisciplinary treat-
ment proposal derived from the holistic diagnosis formulated
according to the current Dutch treatment guidelines [15].
Holistic diagnosis and appropriate treatment had to be based, besides
the patient’s anamnesis and nurse’s observation, on an unbiased
diagnostic process, taking account of the full spectrum of current
symptoms and daily functioning. For this we used a set of standard-
ized questionnaires, including the Health of the Nations Outcome
Scale (HoNOS) [16,17,18]. The screener for intelligence and learning
disabilities (SCIL) [19]), the autism spectrum quotient (AQ) [20],
and the Positive andNegative Syndrome scale (PANSS) [21]. To gain
a complete overview of a patient’s condition, to understand their
possible underlying strengths and vulnerabilities, and to identify
early warning signs, we also interviewed close relatives.
The holistic diagnostic process was undertaken by a multidisci-
plinary team that included a psychiatrist, a psychologist, nurses,
social workers, peer workers, and occupational therapists. This
team reached its holistic diagnoses on the basis of a protocol,
evaluating each case as if it were a new case—in many cases despite
long histories of treatment. In the protocol, the following items
were checked:
1. Whether a patient’s anamnesis (or hetero-anamnesis), biog-
raphy, DSM diagnosis, and psychiatric and psychological
assessments were up-to-date.
2. Whether the current diagnosis fitted with the assessment.
3. The findings of screening instruments, routine outcome mea-
sures such as the HoNOS, adjacent test diagnostics, and devel-
opmental anamnesis.
4. Whether there should have been a second opinion or consul-
tation with colleagues.
As well as a diagnosis according to DSM V categories, a holistic
diagnosiswas also given that contained informationon the following:
1. Demographic data: age, gender, marital status, legal repre-
sentative, and judicial title.
2. The patient’s symptoms and problems, and how he/she
experienced them.
3. Acute precipitating stressors or events.
4. The patient’s own request and desires for help.
5. An estimate of his/her intelligence (IQ) and emotional intel-
ligence (EQ).
6. Relevant underlying life events and traumas, but also protec-
tive factors.
7. Social context, such as partner, family, living circumstances,
work, and daily activities.
8. Addictions.
9. Somatic/physical condition.
10. The patient’s strengths.
11. A working hypothesis that included the categories above and
the protective factors described.
12. The overarching treatment goals.
After the new holistic diagnosis was established, an appropriate
treatment proposal was formulated. All patientswere treated accord-
ing to current guidelines, taking account of customized care when
necessary. Each week, in line with the DITSMImodel, psychoeduca-
tion and evaluation sessions of medication effects and side-effects
were scheduled, in which the team members and sometimes the
patient’s close relatives were present. If a patient experienced adverse
effect, or destabilized after switching medication, low-threshold
contact with the psychiatrist was swiftly arranged. If a patient or
the team noted side-effects, medication could be altered or even
stopped through a shared decision-making process.
As well as a focus on medication change, DITSMI included a
number of regular alternative treatment modalities that could be
provided when necessary, such as psychotherapy, psychosocial
interventions, financial support, and family participation.
Design
The study was conducted in a long-term residential setting and
consisted of a longitudinal cohort study without control group in a
consecutive patient sample. As data sources, we used regular chart
information and routine outcome questionnaires [22].
Setting and participants
The study was conducted in a single 96-bed hospital in the eastern
Netherlands. This apartment complex for long-term residential
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psychiatric patients comprised various individually tailored treat-
ment settings. Care was provided according to the Functional
Assertive Community Treatment (FACT) model [23] All patients
resident in December 2014 were included in the cohort.
Measures
Our aim was to determine how medication use, general function-
ing, and hospital bed utilization were affected by changes in diag-
nosis or appropriate treatment. In the database we included each
change made in DSM IV diagnosis and in appropriate treatment
between 2014 and 2017 (one record per change). Data from elec-
tronic files were extracted between January 1, 2013 and December
31, 2017. We studied four main outcome measures:
1. First, we counted the medication changes in the patient sam-
pled, recording each change as one record per change. Pre-
scriptions for medication were categorized in the following
overall groups: first and second-generation antipsychotics,
anticholinergics, benzodiazepines, anticonvulsants, tricyclic
antidepressants, and selective serotonin reuptake inhibitors
(SSRI). More specifically, we also counted the numbers of
prescriptions for clozapine, olanzapine, lorazepam, and oxaz-
epam, as these are the core of the guidelines.
2. Second, we used the HoNOS, assessed at least once a year. We
analyzed scores above or below cut-off of 13 [16,17,18]. In a
multidisciplinary team meeting in the first year of the study,
nurses were trained in order to increase their skills in admin-
istering the HoNOS.
3. Third, bed utilization from 2012 to 2018 was calculated
according to the length of stay (LOS) before during and after
the DITSMI protocol. We ascertained the time psychiatrist,
psychologist or social worker spent on treatment, direct time
being the time spent in face-to-face contact and indirect time
the time spent on administration or consultations.
4. Fourth, we performed a medical chart review covering a num-
ber of variables, such as side-effects, body mass index (BMI),
comorbid somatic illness/illnesses, psychotherapy provided,
and patient relapse (defined either as seclusion or as placement
in a closed or forensic ward).
Analyses
We analyzed data of 94 patients resident at a long-stay ward on
December 2014. Data were analyzed at two levels, the first being
each treatment change. As a patient was likely to undergo between
one up to five changes over time—either in diagnosis, medication,
or outcome—one record in this database represented one change.
The second level of analysis concerned each individual patient,
where one record represented a patient before the implementation
of the protocol and one record represented the same patient after
implementation. In this second database we deliberately disre-
garded all the changes over time, but chose only the first and last
finding on diagnosis, medication or outcome. “Before” was defined
as chart information andHoNOS scores gathered in 2013 and 2014.
“After” was defined as chart information and HoNOS scores gath-
ered in 2017, or before discharge. Finally, we analyzed differences in
LOS before and after the prevision of DITSMI.
For analysis we used descriptive statistics, performing simple
analyses to compare data gathered before the implementation of the
DITSMImodel with data gathered during and after it. Proportional
differences between the data gathered in these two periods were
tested using chi-square statistics or independent student t test,
when appropriate. Alpha was set at a p value of 0.05.
Results
Sample and patient characteristics
Eight patients in the total sample (n =94) could not be evaluated
because they had been discharged before treatment had started and
follow-up measures could be extracted. Three patients did not
complete the DITSMI model, having died before the end of the
study due to cancer, heart attack, and choking on food (aged 57–61).
The sample thus contained 83 patients for whom there was full data
over the three-year study period. Table 1 presents the descriptive
statistics of the sample, summarizing the main findings gathered
from the medical charts, the diagnoses, and being admitted or not
before and after the DITSMI program. Sixty-nine percent of the
sample (n=57)weremale. Themean age at the start of the studywas
49years (SD=11.8). Mean LOS at the start of the protocol was 20
years. By the end of the study period, 40 of the 83 patients included in
the sample remained on the ward. Twenty-six had been discharged
to psychiatric sheltered-housing facilities, two to a forensic institute,
and four to a nursing home. Eight were living in the community.
Three died after the study, all from cardiac arrest (aged 57–66).
Diagnosis changes
After the implementation of DITSMI, 49% of the DSM IV diagno-
ses and 67% of the treatment proposals changed. Developmental
disorders, psychosis Not Otherwise Specified (NOS), mild or bor-
derline intellectual functioning were diagnosed more often, and
schizophrenia and bipolar disorder were diagnosed less often. As an
example, Figure 1 shows the changes in diagnoses of schizophrenia
before and after the implementation of DITSMI.
Medication changes
Medication changed in 67% of the patients. Use of first-generation
antipsychotic medication decreased from 44% of the patients to 25%.
Use of second-generation antipsychotic medication increased from
56 to 75%. Anticholinergic medication decreased from 35 to 19%. In
line with this, side effects were observed in 38% of the patients before
and in 23% of the patients after the treatment protocol. BMI was
approximately 30 bothbefore andafter. Somatic comorbidity, assessed
in data extracted from 2017, was observed in 53% of the patients.
Table 2 presents changes in medication in more detail. In total,
the 83 patients who had completed the DITSMI model underwent
417 medication changes. Overall, the first change, from first-
generation to second-generation antipsychotics, concerned an
increase in prescriptions of olanzapine. Prescriptions of clozapine
also increased. The decrease in first-generation antipsychotics was
not related to a specific drug. There was also a clear decrease in the
use of anticholinergic medication. With regard to benzodiazepine
use, an increase in lorazepam prescriptions was accompanied by a
decrease in oxazepam prescriptions, but not by an overall increase in
benzodiazepine prescriptions. With respect to anti-depressants and
anticonvulsants medication, no significant changes were observed.
Change in the HoNOS
Table 3 summarizes the HoNOS findings in the sample before and
after the DITSMI protocol. We show the percentage of patients
below cut-off. As one HoNos follow-up measure was lacking,
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comparisons involved 82 patients. In the HoNOS scores, the per-
centage below cut-off of patients whose diagnosis had changed
from 39 to 61%. Correspondingly, the percentage below cut-off
for the change in treatment indication changed from 40 to 60%.
Both changes were significant.
Length of stay and time spent by professionals
Figure 2 presents the trend in theLOSbetween2012 and2018. It shows
a constant line between 2012 and 2014 and a steep decrease between
2015 and 2018 (reduction=41%, standardized beta=0.332, R2 =
0.99, p <0.001) which is associated to the number of discharges.
Table 4 shows that the total direct time (i.e., face-to-face contact)
and indirect time (i.e., administration or consultation) professionals
spent on the patient was 12% greater in the second year than in the
first. In the third year, it was 31% lower than in the second. The extra
investment of 12% in the first year after the implementation of
DITSMI thus reduced total time by 22% in the third year.
Discussion
In this cohort study, we found that the implementation of the
DITSMI model is associated with less medication use, better psy-
chosocial functioning, less time spent by professionals and less
Table 1. Patient characteristics before and after the implementation of the DITSMI model
N = 83 patients Before After p
Mean age 49 (SD 11.8) 52 (SD12.7)
Mean duration of care history 21 (SD 8.9) 24 (SD 8.3)
% men 69% 69%
% partner 18% 18%
Developmental disorder (autism, PDD-NOS ADHD) 6% 16% 0.028
Psychosis NOS 8% 19% 0.043
Schizophrenia 53% 36% 0.019
Schizoaffective disorder 8% 10% 0.773
Bipolar disorder 8% 2% 0.031
Depressive disorder 5% 4% 0.731
Personality disorder 4% 2% 0.173
PTSD 1% 5% 0.093
Mild or borderline intellectual functioning 4% 18% 0.002
Pedophilia – 1% –
Substance-abuse 21% 16% 0.419
% of resident patients 100% 60% <0.001
Patients’ mean (SD) overall length of stay in years 20.2 (8.7) 22.6 (9.0) <0.001
Patients’ mean (SD) length of stay in years since 2000 13.6 (7.8) 15.4 (7.2) <0.001
First-generation antipsychotic medication 44% 25% 0.010
Second-generation antipsychotic medication 56% 75% 0.009
Clozapine 25% 39% 0.030
Anticholinergic medication use 35% 19% 0.023
BMI (mean, SD) 27.7 (5.0) 30.4 (5.3) 0.323
Side effects 38% 23% 0.028
Diagnosis changed 49%
Treatment proposal changed 67%
Medication changed 67%
Somatic comorbidity 53%
Was provided psychotherapy 16%
Relapse as defined by coercive measure or transfer to intensive care wards 15%
Discharge 35%
Deceased 7%
Abbreviations: PDD-NOS, Pervasive Developmental Disorder Not Otherwise Specified; ADHD, attention deficit hyperactivity disorder; Psychosis NOS, Psychosis Not Otherwise Specified BMI,
body mass index; DITSMI, Diagnose, Indicate, Treat, Severe Mental Illness; PTSD, posttraumatic stress disorder; SD, standard deviation.
4 H. M. Veereschild et al.
bed utilization. As 49% of the diagnoses and 67% of the treatment
indications changed, the model also led to a change in medication
use. Similarly, the use of first-generation antipsychotics decreased,
and the use of clozapine and other second-generation antipsy-
chotics increased. The use of anticholinergic medication also
decreased. Psychosocial functioning over time as expressed in the
HoNOS scores showed some improvement. Extra time investment
by professionals in the first year led to a total time reduction of 22%
in the third year. Finally, due to 40 discharges, the LOS fell.
To the best of our knowledge, few naturalistic experiments have
used holistic diagnoses andpractice guidelines of this sort in long-term
residential psychiatric patients, although Scheifes et al. [13] found a
comparable number of changes in a somewhat smaller sample of
patients in a residential setting for the intellectually disabled. Apart
from a single opinion paper [24], no such figures have been reported
within psychiatry. While some studies described efforts to rationalize
medication in patients with SMI [7,13,25], these had little effect. As
reported by Sterrenburg-Van de Nieuwegiessen et al. [3], some
attempts even showed an increase in medication use, often after
intervening crises. The same authors also described that it was com-
mon practice to prescribe considerable amounts of medication to
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Figure 1. Changes in diagnoses of schizophrenia before and after the implementation of the model.
Table 2. Main medication changes before and after the implementation of the DITSMI model
N = 702 prescriptions, 417 changes Before After p value
First-generation antipsychotic medication 81 (22.1%) 42 (12.9%) <0.001
Second-generation antipsychotic medication 64 (21.2%) 100 (30.7%) <0.001
Clozapine 44 (12.0%) 60 (18.2%) 0.021
Olanzapine 14 (3.8%) 36 (11.1%) 0.003
Biperideen 46 (19.9%) 24 (12.9%) 0.026
Benzodiazepines 101 (27.2%) 99 (29.8%) 0.459
Lorazepam 36 (7.1%) 52 (16%) 0.018
Oxazepam 43 (11.7%) 23 (7.1%) 0.033
Anticonvulsants 33 (9.0%) 29 (8.9%) 0.931
Antidepressant medication 34 (9.2%) 24 (7.3%) 0.346
SSRI 24 (6.5%) 19 (5.8%) 0.673
Tri-cyclic antidepressant 10 (2.7%) 5 (1.5%) 0.273
Number of prescriptions (denominator) 370 332
Abbreviations: DITSMI, Diagnose, Indicate, Treat, Severe Mental Illness; SSRI, selective serotonin reuptake inhibitors.
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The construction of the DITSMI model is a simple one: it is an
integrated care model that applies holistic and multidisciplinary
diagnosis and appropriate treatment. It is based on applying cur-
rent guidelines for this group of patients, many of whom do not
receive treatment according to these guidelines. The fact that the
wards in our study were an apartment building may have contrib-
uted to the number of discharges, as this building provided an
environment where patients could get used to living in the com-
munity [26].
In our view, the core and innovating characteristic of the
DITSMI model is that it represents a cultural change from the
palliative-care environment of a nursing-home type of residential
care to an active treatment model. For some patients, it was the first
time they had been treated according to contemporary insights and
the guidelines, even though the former had been developed in the
last two decades.
As literature indicates, sustainable change is not produced
solely by adjusting medication [3]. In addition to structured
holistic diagnosis and drug treatment, the DITSMI model also
focuses on other forms of therapy, including psychoeducation,
psychological treatment, psychosocial treatment, and daytime
activities that are consistent with the latest guidelines. In our view,
once medication has been reduced, this way of working with long-
term residential psychiatric patients provides more sustainable
psychological well-being than would be possible solely by adjust-
ing medication [13].
The DITSMImodel is organized differently from contemporary
care for patients with SMI, which is subject to three main difficul-
ties. First, contemporary treatment focuses primarily on managing
and preventing aggression and stabilizing symptoms. The time
horizons also seem to be unlimited. Second, treatment can be
fragmented, especially between institutional care and ACT or
FACT teams. Third, as general practitioners share some responsi-
bility with mental-health professionals in caring for people with
SMI, communication problems can arise between different care-
givers. In the DITSMI model, in contrast, treatment takes place
within a stablemultidisciplinary treatment team at a single location,
and is limited not only with regard to time but also with regard to its
continuation after treatment goals have been achieved.
Table 3. Association between diagnosis, treatment proposal, and improvement on the HoNOS before and after implementation of the DITSMI model
N = 82 patientsa
HoNOS below cut-offa
p valueBefore After
Diagnosis No change 41 18 (44%) 23 (56%) 0.269
Change in diagnosis 41 16 (39%) 25 (61%) 0.041
Treatment proposal No change 29 13 (45%) 16 (55%) 0.430
Change in treatment proposal 53 21 (40%) 32 (60%) 0.032
82 82
aA cut-off of 12 or less was used [16].
Figure 2. Length of stay of the cohort before, during, and after the treatment time frame.
Table 4. Main changes in the following: the direct time (face-to-face contact)
and indirect time (administration or consultation) spent by professionals; for
this sample over 2015, 2016, and 2017
N = 83 2015 2016 2017 p
Indirect time in minutes 10,773 12,108 8,651 0.001
Direct time in minutes 3,278 3,706 2,302 0.001
Total time in minutes 14,051 15,814 10,952 0.001
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The critical assessment of the medication prescribed under the
model reinforces a more rational prescribing practice. If fewer
psychotropic drugs are prescribed—in terms both of number and
of dosage—side-effects such as sedation may be expected to be
less. To these advantages we can add not only the overall improve-
ment we found in theHoNOS scores, but also the reductions in the
LOS and the need for care. If patients can move out of psychiatric
hospitals into protected living facilities, and if they can receive
outpatient counseling, health-insurance costs are likely to
decrease further. For all these reasons, the large-scale implemen-
tation of theDITSMImodel is likely to lead to amajor reduction in
common healthcare costs. However, an important comment with
regard to the Netherlands is that bed utilization by long-term
residential patients in psychiatric hospitals accounts for the
greater part of these hospitals’ healthcare yields. Financially, many
psychiatric hospitals are thus partly dependent on this group of
patients.
A notable issue in getting DITSMI implemented was the ward
staff’s fears with regard to changing medication. In our view,
however, our study shows that, when done carefully, changing or
reducing medication in a long-stay patient population can be
successful. Medication adjustments are made in a structured fash-
ion, and allow everyone involved to evaluate, think along, and be
engaged in decision-making.
Strengths and limitations of the study
This studywas performed in a categoryof patientswho are sometimes
neglected and do not always receive the care they need. One strength
is that the patients remained includeduntil the end of the 3-year study
period (88%). Another is that this is one of the first studies to focus on
long-term residential psychiatric patients. An earlier study that exam-
ined mechanisms for medication change did not consider the
re-appraisal of diagnoses or the appropriateness of treatment [3].
While the naturalistic design was, in one sense, a limitation, it
also improved clinical validity. We therefore see our results as
valuable to psychiatric clinical practice and organizational devel-
opment.
The DITSMI model is a simple model, which in this case was
implemented at a single mental-health trust by multidisciplinary
treatment teams. It is generalizable to other psychiatric services,
where it can be implemented in full.
The main limitation is the absence of a control group. Our
reason for this was the ethical difficulty of justifying the conduct
of a double-blind study within a single hospital in which part of the
sample received no DITSMI treatment. It is also possible that the
sample was not representative for all residential psychiatric patients
with SMI. Neither do we know the effect of the eight dropouts on
outcome. A third limitation is that generalizability may be prob-
lematic, as we tested the DITSMI model in a single clinic compris-
ing three wards. A fourth limitation is the possibility of a
prescription bias on the part of the participating psychiatrists, as
only two psychiatrists were responsible for prescriptions during the
study. Although they worked on the basis of the current guidelines,
they may also have had their own personal medication preferences.
Fifth, it is conceivable that our estimation of the HoNOS before
implementation was too favorable, and thereby reduced possible
differences. The sensitivity of the HoNOS to measure change in
these long-term residential and outpatient patients with SMI may
also be questioned [18]. Finally, we should add that the sustain-
ability of our findings and the long-term effects of the DITSMI
intervention are yet to be studied.
Conclusions
Over the 3 years in which the DITSMI model was provided to long-
term residential patients, 49% obtained a new diagnosis, 67% a new
treatment proposal, and 67% different medication. Psychosocial
functioning showed a limited change. Bed utilization decreased by
40% when patients moved to sheltered-housing or their own homes
in the community, where they received outpatient treatment. Some
were even discharged from care. Extra time investment by profes-
sionals in the first year led to a total time reductionof 22% in the third
year. Given the results, DITSMI can be recommended as an appro-
priate form of care for all long-term residential psychiatric patients.
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